Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Autoimmun. 2015 May;59:77-84. doi: 10.1016/j.jaut.2015.02.005. Epub 2015 Mar 18.

Revisiting adverse reactions to vaccines: A critical appraisal of Autoimmune Syndrome Induced by Adjuvants (ASIA).

Author information

  • 1Department of Pharmacology and Therapeutics, The University of Melbourne, Victoria, Australia; Friends of Science in Medicine, Melbourne, Victoria, Australia. Electronic address: dhawkes@unimelb.edu.au.
  • 2Friends of Science in Medicine, Melbourne, Victoria, Australia.
  • 3Department of Molecular Immunology, The Walter and Eliza Hall Institute of Medical Research, Victoria, Australia.
  • 4Greenslopes Clinical School of Medicine, University of Queensland, Greenslopes, Queensland, Australia; Department of Renal Medicine, Greenslopes Private Hospital, Greenslopes, Queensland, Australia.
  • 5Australian School of Advanced Medicine, Macquarie Park, NSW, Australia.

Abstract

In 2011 Shoenfeld and Agmon-Levin proposed a new syndrome as a way of grouping together a range of emerging autoimmune diseases with possible adjuvant-associated causes, Autoimmune/Auto-inflammatory Syndrome Induced by Adjuvants (ASIA). At present, there is no evidence to suggest that ASIA syndrome is a viable explanation for unusual autoimmune diseases. Since the initial paper, over 80 publications have discussed ASIA. This systematic review examines the research that has been done to investigate whether ASIA is a broad umbrella term with little clinical significance, or whether there is some underlying mechanism which could be utilised to reduce the occurrence of adjuvant mediated disease. Twenty-seven animal, epidemiological and case studies were reviewed. Unfortunately, a robust animal model of ASIA using biologically relevant doses of adjuvants has yet to be defined. It is also apparent that the broadness of the current ASIA criteria lack stringency and, as a result, very few cases of autoimmune disease could be excluded from a diagnosis of ASIA. The current studies involving human cases are so diverse, in both external stimuli and in resulting conditions, that there is currently a lack of reproducible evidence for any consistent relationship between adjuvant and autoimmune condition. The addition of a mandatory criterion requiring temporal association and clinically relevant adjuvant dose would allow better definition of what constitutes a diagnosis of ASIA.

Copyright © 2015 Elsevier Ltd. All rights reserved.

KEYWORDS:

ASIA; Adjuvant; Aluminium; Neurological damage; Systematic review; Vaccination

PMID:
25794485
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk